• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

作者信息

Klil-Drori Adi J, Yin Hui, Azoulay Laurent, Harnois Michaël, Gratton Michel-Olivier, Del Corpo Alexa, Olney Harold J, Delage Robert, Laneuville Pierre, Mollica Luigina, Busque Lambert, Assouline Sarit E

机构信息

Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.

Department of hematology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.

出版信息

Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29.

DOI:10.1002/ajh.24838
PMID:28670773
Abstract
摘要

相似文献

1
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.慢性髓性白血病患者若未能实现早期分子反应则早期换用二线酪氨酸激酶抑制剂。
Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29.
2
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.转换为第二代酪氨酸激酶抑制剂可改善一线接受伊马替尼治疗的慢性髓性白血病患者的反应和预后，这些患者在3个月时BCR-ABL/ABL比值超过10%。
Cancer Med. 2015 Jul;4(7):995-1002. doi: 10.1002/cam4.440. Epub 2015 Mar 10.
3
Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Leuk Lymphoma. 2014 Jul;55(7):1684-6. doi: 10.3109/10428194.2013.850164. Epub 2013 Nov 14.
4
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Br J Haematol. 2018 Apr;181(2):275-278. doi: 10.1111/bjh.14560. Epub 2017 Feb 17.
5
Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.慢性髓性白血病患者对伊马替尼（格列卫）反应的分子监测：沙特阿拉伯一家三级医疗医院的经验。
Genet Test Mol Biomarkers. 2010 Feb;14(1):67-74. doi: 10.1089/gtmb.2009.0126.
6
Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.在慢性髓性白血病细胞中，Cdc6作为BCR/ABL依赖性生存因子的表达失调。
Tumour Biol. 2017 Jun;39(6):1010428317713394. doi: 10.1177/1010428317713394.
7
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.BCR-ABL1 转录本类型影响伊马替尼一线治疗费城染色体阳性慢性髓性白血病患者的反应和结局。
Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.
8
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.伊马替尼治疗失败后，采用二线第二代酪氨酸激酶抑制剂治疗时，3个月和6个月时的BCR-ABL1转录水平更有助于识别预后不良的慢性髓性白血病患者：单机构报告
Acta Haematol. 2015;134(4):248-54. doi: 10.1159/000430835.
9
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.伊马替尼一线治疗慢性髓性白血病患者的长期疗效。
Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.
10
Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.达沙替尼成功用于慢性髓性白血病伊马替尼诱导的暴发性肝衰竭肝移植术后
J Clin Oncol. 2016 Apr 10;34(11):e97-8. doi: 10.1200/JCO.2013.50.1320. Epub 2014 Sep 29.

引用本文的文献

1
BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.BCR-ABL1 转录本水平在 4 周时对特定时间的反应和预测接受各种酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病患者的生存具有预后意义。
Cancer Med. 2018 Oct;7(10):5107-5117. doi: 10.1002/cam4.1753. Epub 2018 Aug 31.